GeoVax Labs is a biotechnology business based in the US. GeoVax Labs shares (GOVX) are listed on the NASDAQ and all prices are listed in US Dollars. GeoVax Labs employs 14 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.51 - $1.39 |
| 50-day moving average | $0.57 |
| 200-day moving average | $0.66 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.74 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5177 from 2023-09-22
| 1 week (2023-09-18) | -4.04% |
|---|---|
| 1 month (2023-08-25) | -7.55% |
| 3 months (2023-06-23) | -12.98% |
| 6 months (2023-03-24) | -24.97% |
| 1 year (2022-09-23) | -54.98% |
|---|---|
| 2 years (2021-09-24) | -88.02% |
| 3 years (2020-09-25) | 2.94 |
| 5 years (2018-09-25) | 480000 |
| Gross profit TTM | $81,526 |
|---|---|
| Return on assets TTM | -45.44% |
| Return on equity TTM | -85.79% |
| Profit margin | 0% |
| Book value | $0.65 |
| Market Capitalization | $14.3 million |
TTM: trailing 12 months
We're not expecting GeoVax Labs to pay a dividend over the next 12 months.
You may also wish to consider:
GeoVax Labs's shares were split on a 1:20 basis on 25 September 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.
Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $0.51 up to $1.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 2.9353. This would suggest that GeoVax Labs's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put GeoVax Labs's beta into context you can compare it against those of similar companies.
GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.